期刊文献+

白三烯受体拮抗剂联合舒利迭吸入治疗老年哮喘的临床分析 被引量:8

下载PDF
导出
摘要 探讨白三烯受体拮抗剂联合舒利迭吸入治疗老年哮喘的临床效果。选取老年哮喘患者34例,随机分为观察组和对照组各17例。观察组给予患者白三烯受体拮抗剂联合舒利迭吸入进行治疗,对照组单纯采用舒利迭进行治疗,对比两组临床治疗效果。对照组总有效率为82.3%,观察组总有效率为94.1%,两组比较,差异显著,具有统计学意义(P<0.05)。白三烯受体拮抗剂联合舒利迭吸入治疗老年哮喘疗效确切,能显著改善患者的心理状况及哮喘症状,从而提高患者的生存质量。
作者 崔良臣
出处 《现代诊断与治疗》 CAS 2013年第16期3672-3673,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献3

二级参考文献14

  • 1Vachier I, Kumlin M, Dahlen SE, et al. High levels of urinary leukotriene FA excretion in steroid treated patients with severe asthma [ J]. Respir Med, 2003 ;97 ( 11 ) : 1225-9.
  • 2Busse W, Kraft M. Cysteingl leukotrienes in allergic inflammation:strate- gic target for therapy[ J]. Chest ,2005 ; 127 (4) : 1312-26.
  • 3Kabesch M, Schedel M, Carrd O. IL-4/IL-13 Pathway genetics strongly in- fluence serum IgE levels and childhood asthma[ J]. J Allergy Clin Immu- nol,2006 ; 117 ( 2 ) :269-74.
  • 4Yen IH, Yelin EH, Katz P,et al. Perceived neighborhood problems and quality of life, physical functioning, and depressive symptoms among a- dults with asthma [ J ]. Am J Public Health,2006 ;96 (5) :873-9.
  • 5Reiss TF, Chervinsky P, Dockhorn RJ,et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group[J].Arch Intern Med,1998,158(11):1213-1220.
  • 6Holgate ST, Bradding P, Sampson AP.Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy[J].J Allergy Clin Immunol,1996,98(1):1-13.
  • 7Spector SL. Leukotriene inhibitors and antagonists in asthma[J].Ann Allergy Asthma Immunol,1995,75(6 Pt 1): 463-473.
  • 8支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185. 被引量:2519
  • 9王美卿,魏芬生.哮喘患儿IL-12和IL-13水平的变化及糖皮质激素对其的影响[J].浙江临床医学,2008,10(10):1349-1350. 被引量:4
  • 10张霞,徐艳,王玲,薛玉文,李玉.吸入激素对哮喘和慢性阻塞性肺病患者血清白介素-8、白介素-13变化的影响[J].中国老年学杂志,2008,28(20):2020-2022. 被引量:12

共引文献38

同被引文献82

  • 1王靓雅.小剂量糖皮质激素联合茶碱治疗老年哮喘的疗效观察[J] .中国药物经济学,2013,36(1):229-230.
  • 2中华医学会呼吸病学分会.哮喘学组支气管哮喘防治指南(方案)[J].中华结核和呼吸杂志,2008,31(3):57-63.
  • 3Stupka E, deShazo R. Asthma in seniors: Part 1. Evidence for underdiagnosis,undertreatment, and increasing morbidity and mortality[J]. AmJ Med, 2009,122(1): 6-11.
  • 4Scichilone N, Pedone C, Battaglia S, et al. Diagnosis and managementof asthma in the elderly[J].E ut J Intern Med, 2014, 25(4): 336-42.
  • 5Haughneya J, Aubierb M, J0rgensen L, et al. Comparing asthma treatmentin elderly versus younger patients [J]. Respiratory Medicine, 2011,105(6): 838-45.
  • 6Yoshida M, Nakano T, Fukuyama S, et al. Effects of tioixopium on lungfunction in severe asthmatics with or without emphysematous changes[J].Palm Hwrmacol Ther, 2013, 26(2): 159-66.
  • 7Creticos P, Knobil K, Edwards LD, et al. Loss of response to treatmentwith leukotriene receptor antagonists but not inhaled corticosteroids inpatients over 50 years of age [J]. Ann Allergy Asthma Immunol, 2002,88(4): 401-9.
  • 8Korenblat PE, Kemp JP, Scherger JE, et al. Effect of age on responseto zaflrlukast in patients with asthma in the Accolate Clinical Experienceand Pharmacoepidemiology Trial (ACCEPT)[J]. Ann Allergy AsthmaImmunol, 2000, 84(2): 217-25.
  • 9Hanania NA. Targeting airway inflammation in asthma: current and futuretherapies[J]. Chest, 2008, 133(4); 989-98.
  • 10Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy:when is enough, enough- [J]. Ann Allergy Asthma Immunol72007, 98(5): 416-26.

引证文献8

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部